Kura Oncology Inc (OQ:KURA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO CA 92130
Tel: N/A
Website: https://www.kuraoncology.com
IR: See website
<
Key People
Troy E. Wilson
Chairman of the Board, President, Chief Executive Officer
Kathleen Ford
Chief Operating Officer
Stephen Dale
Chief Medical Officer
Brian Powl
Chief Commercial Officer
Teresa Bair
Chief Legal Officer, Secretary
 
Business Overview
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
Financial Overview
For the fiscal year ended 31 December 2023, Kura Oncology Inc revenues was not reported. Net loss increased 12% to $152.6M. Higher net loss reflects Discovery and development of precision medicines segment loss increase of 19% to $165.8M, United States segment loss increase of 19% to $165.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.03 to -$2.08.
Employees: 142 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $932.25M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$164.96M as of Dec 31, 2023
Net annual income (TTM): -$152.63M as of Dec 31, 2023
Free cash flow (TTM): -$124.99M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 76,180,620 as of Apr 8, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.